Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects

Kyoung Ah Kim, Pil Whan Park, Hyung Kee Kim, Jong Myung Ha, Ji-Young Park

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Previous in vitro studies have demonstrated that quercetin inhibits CYP2C8, but there are no available data to indicate that quercetin inhibits CYP2C8 in vivo. The effect of long-term use of quercetin on the pharmacokinetics of rosiglitazone was evaluated. After administration of quercetin or watched placebo for 3 weeks in a crossover manner, rosiglitazone 4 mg was administered, and the pharmacokinetics of rosiglitazone and N-desmethylrosiglitazone were determined. For AUC, AUClast, and Cmax, the geometric mean ratios (90% confidence interval) for (quercetin + rosiglitazone/ placebo + rosiglitazone) were 0.98 (0.92, 1.05), 0.99 (0.92, 1.05), and 1.01 (0.88, 1.14), respectively. Metabolic conversion based on the AUC ratio of N-desmethylrosiglitazone/ rosiglitazone in the quercetin phase (0.49 + 0.17) was similar to that of the placebo phase (0.47 ± 0.14) (P = .574). Even though the acute interaction that would occur during the first few days of concurrent administration of quercetin cannot be excluded, these results indicate that long-term use of quercetin does not inhibit CYP2C8 activity, and the usage has little possibility of interacting with drugs that are metabolized by CYP2C8, including rosiglitazone.

Original languageEnglish
Pages (from-to)941-946
Number of pages6
JournalJournal of Clinical Pharmacology
Volume45
Issue number8
DOIs
Publication statusPublished - 2005 Aug 1
Externally publishedYes

Fingerprint

rosiglitazone
Quercetin
Healthy Volunteers
Pharmacokinetics
Placebos
Area Under Curve
Cytochrome P-450 CYP2C8

Keywords

  • Cytochrome P450 2C8 (CYP2C8)
  • Drug interaction
  • Quercetin
  • Rosiglitazone

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. / Kim, Kyoung Ah; Park, Pil Whan; Kim, Hyung Kee; Ha, Jong Myung; Park, Ji-Young.

In: Journal of Clinical Pharmacology, Vol. 45, No. 8, 01.08.2005, p. 941-946.

Research output: Contribution to journalArticle

Kim, Kyoung Ah ; Park, Pil Whan ; Kim, Hyung Kee ; Ha, Jong Myung ; Park, Ji-Young. / Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. In: Journal of Clinical Pharmacology. 2005 ; Vol. 45, No. 8. pp. 941-946.
@article{b1cf1ec482164e83afb5e6e8d302610e,
title = "Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects",
abstract = "Previous in vitro studies have demonstrated that quercetin inhibits CYP2C8, but there are no available data to indicate that quercetin inhibits CYP2C8 in vivo. The effect of long-term use of quercetin on the pharmacokinetics of rosiglitazone was evaluated. After administration of quercetin or watched placebo for 3 weeks in a crossover manner, rosiglitazone 4 mg was administered, and the pharmacokinetics of rosiglitazone and N-desmethylrosiglitazone were determined. For AUC∞, AUClast, and Cmax, the geometric mean ratios (90{\%} confidence interval) for (quercetin + rosiglitazone/ placebo + rosiglitazone) were 0.98 (0.92, 1.05), 0.99 (0.92, 1.05), and 1.01 (0.88, 1.14), respectively. Metabolic conversion based on the AUC ratio of N-desmethylrosiglitazone/ rosiglitazone in the quercetin phase (0.49 + 0.17) was similar to that of the placebo phase (0.47 ± 0.14) (P = .574). Even though the acute interaction that would occur during the first few days of concurrent administration of quercetin cannot be excluded, these results indicate that long-term use of quercetin does not inhibit CYP2C8 activity, and the usage has little possibility of interacting with drugs that are metabolized by CYP2C8, including rosiglitazone.",
keywords = "Cytochrome P450 2C8 (CYP2C8), Drug interaction, Quercetin, Rosiglitazone",
author = "Kim, {Kyoung Ah} and Park, {Pil Whan} and Kim, {Hyung Kee} and Ha, {Jong Myung} and Ji-Young Park",
year = "2005",
month = "8",
day = "1",
doi = "10.1177/0091270005278407",
language = "English",
volume = "45",
pages = "941--946",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "8",

}

TY - JOUR

T1 - Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects

AU - Kim, Kyoung Ah

AU - Park, Pil Whan

AU - Kim, Hyung Kee

AU - Ha, Jong Myung

AU - Park, Ji-Young

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Previous in vitro studies have demonstrated that quercetin inhibits CYP2C8, but there are no available data to indicate that quercetin inhibits CYP2C8 in vivo. The effect of long-term use of quercetin on the pharmacokinetics of rosiglitazone was evaluated. After administration of quercetin or watched placebo for 3 weeks in a crossover manner, rosiglitazone 4 mg was administered, and the pharmacokinetics of rosiglitazone and N-desmethylrosiglitazone were determined. For AUC∞, AUClast, and Cmax, the geometric mean ratios (90% confidence interval) for (quercetin + rosiglitazone/ placebo + rosiglitazone) were 0.98 (0.92, 1.05), 0.99 (0.92, 1.05), and 1.01 (0.88, 1.14), respectively. Metabolic conversion based on the AUC ratio of N-desmethylrosiglitazone/ rosiglitazone in the quercetin phase (0.49 + 0.17) was similar to that of the placebo phase (0.47 ± 0.14) (P = .574). Even though the acute interaction that would occur during the first few days of concurrent administration of quercetin cannot be excluded, these results indicate that long-term use of quercetin does not inhibit CYP2C8 activity, and the usage has little possibility of interacting with drugs that are metabolized by CYP2C8, including rosiglitazone.

AB - Previous in vitro studies have demonstrated that quercetin inhibits CYP2C8, but there are no available data to indicate that quercetin inhibits CYP2C8 in vivo. The effect of long-term use of quercetin on the pharmacokinetics of rosiglitazone was evaluated. After administration of quercetin or watched placebo for 3 weeks in a crossover manner, rosiglitazone 4 mg was administered, and the pharmacokinetics of rosiglitazone and N-desmethylrosiglitazone were determined. For AUC∞, AUClast, and Cmax, the geometric mean ratios (90% confidence interval) for (quercetin + rosiglitazone/ placebo + rosiglitazone) were 0.98 (0.92, 1.05), 0.99 (0.92, 1.05), and 1.01 (0.88, 1.14), respectively. Metabolic conversion based on the AUC ratio of N-desmethylrosiglitazone/ rosiglitazone in the quercetin phase (0.49 + 0.17) was similar to that of the placebo phase (0.47 ± 0.14) (P = .574). Even though the acute interaction that would occur during the first few days of concurrent administration of quercetin cannot be excluded, these results indicate that long-term use of quercetin does not inhibit CYP2C8 activity, and the usage has little possibility of interacting with drugs that are metabolized by CYP2C8, including rosiglitazone.

KW - Cytochrome P450 2C8 (CYP2C8)

KW - Drug interaction

KW - Quercetin

KW - Rosiglitazone

UR - http://www.scopus.com/inward/record.url?scp=23044511374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044511374&partnerID=8YFLogxK

U2 - 10.1177/0091270005278407

DO - 10.1177/0091270005278407

M3 - Article

VL - 45

SP - 941

EP - 946

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 8

ER -